Bio-Techne To Host Conference Call On November 5, 2020 To Announce First Quarter 2021 Financial Results
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on November 5, 2020, at 8:00 a.m. CST to discuss its first quarter 2021 financial results. Investors can access the live call via phone or online. A replay will be available after the call until December 5, 2020. Bio-Techne, a leader in developing purified proteins and diagnostic products, reported approximately $739 million in net sales for fiscal 2020 and employs around 2,300 staff worldwide.
- Bio-Techne generated approximately $739 million in net sales in fiscal 2020.
- Strong product portfolio includes cytokines, antibodies, and genomic tools.
- None.
MINNEAPOLIS, Oct. 13, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, November 5, 2020, at 8:00 a.m. CST to review first quarter 2021 financial results.
Access to the discussion may be obtained as follows:
Time: | 8:00 a.m. CST |
Date: | November 5, 2020 |
Dial-in: | 1-855-327-6837 or 1-631-891-4304 (for international callers) |
Conference ID: | 10011451 |
Webcast: |
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 10011451.
The replay will be available from 11:00 a.m. CST on Thursday, November 5, 2020 until 11:00 p.m. CST on Saturday, December 5, 2020.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx®Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Senior Director, Investor Relations & Corporate Development |
612-656-4416 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-november-5-2020-to-announce-first-quarter-2021-financial-results-301150865.html
SOURCE Bio-Techne Corporation
FAQ
When is Bio-Techne's conference call for first quarter 2021 financial results?
How can I access Bio-Techne's conference call?
What were Bio-Techne's net sales in fiscal 2020?
What is the duration of the replay for Bio-Techne's conference call?
